24 results about "Fibromyalgia" patented technology

Provided are methods for treating fibromyalgia or one or more symptoms thereof, that involve the administration of psychedelics, such as psilocybin or a metabolite thereof, and related uses of the psychedelics. The disclosure in some aspects also relates to methods for identifying subjects for treatment of fibromyalgia with administration of psychedelics. In some aspects, the treatment also involves psychotherapy. In some aspects, the subject receiving the treatment is assessed for various indicators, such as observer-rated and subject-reported outcomes, biological and clinical indicators, and combinations thereof.

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

Methods for treating fibromyalgia and one or more of its associated symptoms of pain, sleep disturbance and / or fatigue comprising administering to a subject in need thereof, 5.6 mg cyclobenzaprine HCl per day in one or more dosage units by transmucosal administration, the cyclobenzaprine HCl being in a form of a eutectic, and the one or more dosage units further comprising a basifying agent.

The present invention relates to the compound 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological pathologies including grade IV glioblastoma with native IDH, grade 3 glioma, embryonal tumour, pituitary tumour, meningioma, haemangiopericytoma, haemangioblastoma, mesothelioma, bile duct adenocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, urachal cancer, adenocarcinoma of the bladder and oesophageal cancer, and for the treatment of neuropathic pain caused by diabetic peripheral neuropathy, spinal cord injury, post-herpetic neuralgia, chemotherapeutic agent, antitumour agent, cancer, fibromyalgia or hepatitis. The present invention also relates to the pharmaceutical composition comprising 2-hydroxy-octadecene-9-cis-oate.

The invention provides methods, kits and reagents for diagnosing fibromyalgia (FM) in an individual by determining whether the levels of one or more cytokines in the individual are altered, as compared to control levels. The altered level(s) or patterns of expression of the cytokines measured in the affected individual compared to the level from the control is predictive / indicative of FM in the individual.

Provided herein are compounds of Formula (I) or pharmaceutically acceptable salts thereof. Further disclosed are nanoparticles comprising one of the compounds and methods of using the same to treat drug addiction, drug dependence, drug excess, opioid use disorder, pain, chronic pain, fibromyalgia, arthritis, or obesity. (I)

The present disclosure relates to diagnostic and therapeutic applications of photobiomodulation and light therapies such as red-light therapy and electrical stimulation devices. Application areas include gut, uterine and other pelvic conditions, back pain, endometriosis, fibromyalgia, etc. The methods and devices disclosed herein are used for delivering targeted therapy using personalized and adjustable treatment protocols which may use features such as real-time monitoring and closed-loop feedback. The devices described herein can be worn discretely to deliver therapy. The present disclosure also includes artificial intelligence and machine learning-based methods for such diagnostic and therapeutic applications.

To provide a therapeutic agent for myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS) and fibromyalgia.SOLUTION: A therapeutic agent for a disease selected from myalgic encephalomyelitis / chronic fatigue syndrome and fibromyalgia, comprising 2-amino-2 - [2 - (4-heptyloxy-3-trifluoromethylphenyl) ethyl] propane-1, 3-diol or pharmaceutically acceptable salts thereof.SELECTED DRAWING: Figure 1

Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.

Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.

Methods and systems for improving medical conditions by delivering a focused ultrasound signal to target sites of the autonomic nervous system. The focused ultrasound signal can have a mechanical index of between about 0.1 to about 5.0 and / or an acoustic pressure of between about 0.1 MPa to about 2.5 MPa. The medical condition can comprise chronic or refractory rhinitis, chronic rhinosinusitis, autonomic instability / autonomic dysfunction, functional gastrointestinal disorders, inflammatory disorders, immune disorders (including improving cancer and infections by neuromodulation of immune function), complex regional pain syndrome, post-traumatic stress disorder (PTSD), anxiety and anxiety-associated disorders, autism, fibromyalgia, uterine function, metabolic disorder, urinary incontinence or binge eating.

The digital therapy system collects data about the user from a user device. For example, the digital therapy system may collect data about the user's physical and mental health from the user through the user device. The digital therapy system then generates biomarker characteristics for the user. Biomarker characteristics are characteristics that describe a user's FM. The digital therapy system may generate the biomarker characteristics for a user by applying a biomarker model to data about the user. The digital therapy system can use the biomarker characteristics to determine a treatment plan for the user. A treatment plan is a set of treatment assignments that aid a user in alleviating or coping with symptoms from their FM in accordance with CBT techniques. The digital therapy system may also adjust the treatment plan for the user based on additional data that the digital therapy system receives.

The present invention relates to dosing regimens and methods of using LY3154207, also described as 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2 (1H)-yllethanone, and / or pharmaceutical compositions thereof, for treatment of dopaminergic central nervous system disorders. Dopaminergic CNS disorders of the present dosing regimen methods include Parkinson's Disease, Alzheimer's Disease, Lewy body dementia (LBD), Vascular Dementia, Schizophrenia, ADHD, Depression, Autism, chronic musculoskeletal pain, fibromyalgia, cognitive impairment disorders, sleep disorders, excessive daytime sleepiness, narcolepsy, shift work disorder, traumatic brain injury, chronic traumatic encephalopathy, obesity and appetite regulation, mood disorders, lethargy, apathy, and addiction disorders.

The present invention relates to the compound 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological conditions including grade IV glioblastoma, grade 3 glioma, embryonal tumor, pituitary tumor, meningioma, hemangiopericytoma, hemangioblastoma, mesothelioma, cholangiocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, urinary tract cancer, bladder adenocarcinoma, and esophageal cancer, as well as for use in the treatment of peripheral diabetic neuropathy, spinal cord injury, postherpetic neuralgia, chemotherapeutic agents, antitumor agents, cancer, fibromyalgia, or neuropathic pain caused by hepatitis. The present invention also relates to pharmaceutical compositions comprising 2-hydroxy-octadecene-9-cis-oate.

Described herein are formulations for treating, preventing, or ameliorating one or more of irritable bowel syndrome (IBS), rheumatoid arthritis (RA), fibromyalgia, post-traumatic stress disorder, PTSD

Biomarkers for post-traumatic stress disorder (PTSD) and biomarkers for fibromyalgia (FM), which is associated with a high rate of PTSD, have been identified by narrowing down biomarker genes from PTSD-related gene database on the basis of biological events related to disease conditions. In addition, Chinese herbal medicines that are potential therapeutic agents for PTSD have been identified through the examination and comparison of gene induction by Chinese herbal medicines and antipsychotics in human keratinocytes. The present method can provide: biomarkers applicable as indicators for the diagnosis and the development of therapeutic agents for PTSD and FM; effective Chinese herbal medicines for PTSD and FM; and a screening method for therapeutic agents for PTSD and FM.

The present invention aims to provide a therapeutic agent for myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS) and fibromyalgia. A therapeutic agent for a disease selected from myalgic encephalomyelitis / chronic fatigue syndrome, and fibromyalgia, containing 2-amino-2-[2-(4-heptyloxy-3-trifluoromethylphenyl)ethyl]propane-1,3-diol or a pharmaceutically acceptable salt thereof.

The present disclosure provides methods and systems for diagnosing and treating fibromyalgia in a patient. In one method, a pressure value is obtained for the patient, wherein the pressure value is determined by inserting a needle of a device into a location in the patient, injecting saline solution into the patient at the location, and measuring a pressure at the location; and fibromyalgia is diagnosed in the patient if the pressure at the location exceeds a threshold pressure value. The present disclosure also provides a device for use in the methods of the disclosure. One such device includes a needle, a syringe including a saline solution, a tube positioned between the syringe and the needle, and a pressure sensor configured to obtain a pressure value at a muscle location of a patient.

The application discloses a composite probiotic composition and a preparation method and application thereof, and belongs to the technical field of biological medicine. The composition comprises a double-layer microencapsulated probiotic component, a postbiotic component and a prebiotic component; the probiotic is selected from Akkermansia, Lactobacillus plantarum and Lactobacillus rhamnosus, the postbiotic is deoxycholic acid and DL-tryptophan, and the prebiotic comprises inulin and galactooligosaccharide. The double-layer microcapsule is coated with a sodium alginate-chitosan inner layer and a pH-sensitive outer layer, so that gastric acid protection and intestinal site-specific release are realized. The three components of the application are synergistic, can repair the intestinal barrier, regulate the key pathways of the intestinal-pain axis, significantly improve the pain threshold and inhibit inflammation, and can be used for preparing a drug for preventing and treating neuropathic pain, fibromyalgia and other chronic pain.

Compositions and pharmaceutical forms for the treatment of fibromyalgia, rheumatoid arthritis, systemic lupus erythematosus and autoimmune diseases associated with pain and inflammation of the muscles and joints with natural active ingredients in the form of lyophilized powders of aqueous extracts of Dandelion (Taraxacum officinale), Watermelon (Citrullus lanatus), Mapuey or white yam, (Dioscorea trifid), Licorice (Glycyrrhiza glabra), tomato (Solanum lycopersicum) and bay leaves (Laurus nobilis), as well as procedures for obtaining and preparing associated with the development of the different compositions and pharmaceutical forms.

The invention provides compositions and methods for administering therapeutic compounds, particularly cyclobenzaprine or amitriptyline, for absorption through the mucosa, wherein the compositions contain a basifying agent in addition to the therapeutic agent. The compositions and methods have a number of unexpected pharmacokinetic benefits over oral administration. Methods of treating fibromyalgia in a human subject are also provided.

Methods and systems for improving medical conditions by delivering a focused ultrasound signal to target sites of the autonomic nervous system. The focused ultrasound signal can have a mechanical index of between about 0.1 to about 5.0 and / or an acoustic pressure of between about 0.1 MPa to about 2.5 MPa. The medical condition can comprise chronic or refractory rhinitis, chronic rhinosinusitis, autonomic instability / autonomic dysfunction, functional gastrointestinal disorders, inflammatory disorders, immune disorders (including improving cancer and infections by neuromodulation of immune function), complex regional pain syndrome, post-traumatic stress disorder (PTSD), anxiety and anxiety-associated disorders, autism, fibromyalgia, uterine function, metabolic disorder, urinary incontinence or binge eating.